Catalog No.S1681 Synonyms: 5-Aminosalicylic acid
Molecular Weight(MW): 153.14
Mesalamine is a specific inhibitor of TNFα-induced IKK activity, used to treat inflammatory bowel disease.
Purity & Quality Control
Choose Selective IκB/IKK Inhibitors
|Description||Mesalamine is a specific inhibitor of TNFα-induced IKK activity, used to treat inflammatory bowel disease.|
Mesalamine inhibits the enzyme 3-hydroxysteroid dehydrogenase, involved in the reversible conversion between DHP and THP, and therefore may affect the local actions of DHP and THP in the brain. Mesalamine, an anti-inflammatory aminosalicylate, dose-dependently inhibits IL-1-stimulated NF-kappaB-dependent transcription without preventing IkappaB degradation or nuclear translocation and DNA binding of the transcriptionally active NF-kappaB proteins, RelA, c-Rel, or RelB. Mesalamine is found to inhibit IL-1-stimulated RelA phosphorylation.  Mesalamine increases cell adhesion which is measured by cell adhesion assay and transcellular-resistance measurement. Mesalamine treatment restores membranous expression of adhesion molecules E-cadherin and β-catenin.  Mesalamine or sulfasalazine (2 mM), but not sulfapyridine, significantly reduces the expression of the TC22 transcript and significantly reduces the expression of TC22 protein in a dose-dependent and reversible manner.  Mesalamine induces membranous expression of E-cadherin and increases intercellular adhesion. Mesalamine activity modulates E-cadherin glycosylation and increases both mRNA and protein levels of GnT-III and its activity as detected by increased E4-lectin reactivity.  Mesalamine (0.1-1 mM) shows considerable inhibition of peroxynitrite-mediated luminol chemiluminescence in a dose-dependent fashion, suggesting that Mesalamine is able to directly scavenge the peroxynitrite. Mesalamine only at higher concentration (1 mM) inhibits the hydroxyl radical adduct while shifting Electron paramagnetic resonance (EPR) spectra. 
-  Egan LJ, et al. J Biol Chem,?999, 274(37), 26448-26453.
-  Khare V, et al. Biochem Pharmacol,?013, 85(2), 234-244.
-  Das KK, et al. Mol Pharmacol,?009, 76(1), 183-191.
|In vitro||DMSO||31 mg/mL (202.42 mM)|
|Ethanol||31 mg/mL (202.42 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT00514982||Withdrawn||Hermanski-Pudlak Syndrome|Colitis|Cytokines|Lymphocytes|Drug Evaluation||National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)||August 7 2007||Phase 2|
|NCT03415711||Recruiting||Ulcerative Colitis||VSL Pharmaceuticals|Actial Farmaceutica S.r.l.||April 28 2017||Not Applicable|
|NCT03070574||Recruiting||Colorectal Cancer||Christoph Gasche|Prof. Dr. Gabriela Möslein Germany|Prof. Dr. Hans Vasen The Netherlands|Prof. Dr. med. Jan Lubinski Poland|Prof. Dr. med. Yaron Niv Israel|Univ. Prof. Dr. Judith Karner-Hanusch Austria|Ann-Sofie Backman MD PhD Sweden|Medical University of Vienna||September 2017||Phase 2|
|NCT02910245||Recruiting||Colitis Ulcerative||Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|ZonMw: The Netherlands Organisation for Health Research and Development||November 2016||Phase 3|
|NCT02522780||Active not recruiting||Ulcerative Colitis||Ferring Pharmaceuticals||February 2016||Phase 3|
|NCT02683733||Unknown status||Ulcerative Colitis||Asian Institute of Gastroenterology India||February 2016||Phase 3|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.